RITA Clinical Trials

Size	Price	Qty
5mg	USD 170
50mg	USD 970

Clinical Trials

Multiple clinical trials evaluate RITA-associated interventions across oncology and hematology indications—including multiple myeloma, acute myeloid leukemia, and non-small cell lung cancer—as well as non-oncological conditions such as ST-elevation myocardial infarction, severe asthma, and hypercholesterolemia. Spanning Phase 1, Phase 2, and Phase 4 stages alongside protocols without phase designations, recruitment statuses range from actively recruiting to completed. These studies are sponsored by a mix of academic institutions, university hospitals such as Assistance Publique - Hôpitaux de Paris, and industry partners like Advice Pharma Group srl.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05211401	RECRUITING	ST Elevated Myocardial Infarction	Assistance Publique - Hôpitaux de Paris	2022-06-01	PHASE2
NCT05260203	COMPLETED	Multiple Myeloma; Solitary Plasmacytoma; Amyloidosis; Chronic Myeloid Leukemia; Chronic Lymphocytic Leukemia; T Cell Non-Hodgkin Lymphoma; Lymphocytic Lymphoma; Hodgkin Lymphoma; B-cell Non Hodgkin Lymphoma; Acute Myeloid Leukemia; Myelodysplasia; Chronic Myeloproliferative Disorder; Treatment Adherence; Treatment Adherence and Compliance	Advice Pharma Group srl	2022-06-04
NCT05153551	COMPLETED	Autism Spectrum Disorder	University of Michigan	2022-01-27
NCT05260203	Completed	Multiple Myeloma\|Solitary Plasmacytoma\|Amyloidosis\|Chronic Myeloid Leukemia\|Chronic Lymphocytic Leukemia\|T Cell Non-Hodgkin Lymphoma\|Lymphocytic Lymphoma\|Hodgkin Lymphoma\|B-cell Non Hodgkin Lymphoma\|Acute Myeloid Leukemia\|Myelodysplasia\|Chronic Myeloproliferative Disorder\|Treatment Adherence\|Treatment Adherence and Compliance	Advice Pharma Group srl	2022-06-04	Not Applicable
NCT05153551	Completed	Autism Spectrum Disorder	University of Michigan\|Blue Cross Blue Shield of Michigan Foundation	2022-01-27	Not Applicable
NCT03806127	Completed	Irritable Bowel Syndrome	Urovant Sciences GmbH	2018-12-31	Phase 2
NCT00571987	COMPLETED	Cancer of the Breast	University of Arkansas	2004-09	PHASE1; PHASE2
NCT01051986	COMPLETED	Coronary Artery Disease	Seoul National University Hospital	2008-09
NCT01524601	COMPLETED	Disorder Related to Renal Transplantation; Hypercholesterolemia	University of Oslo School of Pharmacy	2012-02	PHASE4
NCT00779025	Completed	Coitus	Johnson & Johnson Consumer and Personal Products Worldwide	2008-01	Not Applicable
NCT00690703	COMPLETED	Non Small Cell Lung Cancer; Pulmonary Metastases	Angiodynamics, Inc.	2001-07	PHASE2

(data from https://clinicaltrials.gov, updated on 2026-08-12)

Check the RITA product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

RITA directly binds to p53, thereby blocking its interaction with MDM2 and preventing MDM2-mediated p53 ubiquitination and degradation. The resulting stabilization of p53 activates downstream JNK signaling and induces apoptosis, suppressing tumor cell growth in oncological settings including multiple myeloma, acute myeloid leukemia, and non-small cell lung cancer evaluated in clinical research.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).